BRCA1 and breast carcinoma: The AhR enhances the release of amphiregulin (AREG) and specific chemokines including granulocyte-colony stimulating factor (G-CSF), CXCL1/2/5, and CCL2/5 in the TME in human breast cancer tissue bearing BRCA1 mutation, which may facilitate the activation of protumorigenic and angiogenic TAMs [36].